Selexipag real-world experience in patients over 75 yrs with pulmonary arterial hypertension (PAH)

PAH patients over the age of 75 yrs are generally excluded from clinical trials.Here we present characteristics and outcomes of patients >75 yrs from EXPOSURE (EUPAS 19085), an international, observational PAH study.Between Sep 2017 and Nov 2020, out of the 382 new selexipag users with follow-up information, 41 (11%) were >75 yrs. Patient characteristics at selexipag initiation are in the table. Selexipag was initiated as triple combination, double combination and monotherapy in 35 (85%), 3 (7%) and 2 (5%) patients, respectively. During the mean (SD) exposure period of 10.3 (8.9) months, 16 (39%) patients discontinued selexipag. There were 15 (37%) patients hospitalised, with a median (Q1, Q3) time to first hospitalisation of 182 (29, 337) days. Four (10%) patients died; mortality rate (95% CI) was 11.4 (3.1–29.1) per 100 person-yrs.These contemporary data contribute to an area where evidence is scarce, suggesting that treatment of elderly patients with selexipag as part of a triple combination regimen is feasible with careful management of disease characteristics and comorbidity burden. >75 yrs n=41Age, yrs*79 (76–87)Female, n (%)28 (68)Time from diagnosis, yrs*1.7 (0–13) PAH aetiology, n (%) Idiopathic/heritable Drug/toxin-induced Connective tissue disease Congenital heart disease 26 (63) 1 (2) 12 (29) 2 (5) WHO FC, n I/II, n (%) III/IV, n (%) 35 0/6 (17) 26 (74)/3 (9) 6-minute walk distance, n m* 23 240 (80–475) History of cardiovascu...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pulmonary hypertension Source Type: research